CA2979293C - Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d) - Google Patents

Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d) Download PDF

Info

Publication number
CA2979293C
CA2979293C CA2979293A CA2979293A CA2979293C CA 2979293 C CA2979293 C CA 2979293C CA 2979293 A CA2979293 A CA 2979293A CA 2979293 A CA2979293 A CA 2979293A CA 2979293 C CA2979293 C CA 2979293C
Authority
CA
Canada
Prior art keywords
treatment
obesity
diabetes
type
pancreatic endocrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2979293A
Other languages
English (en)
French (fr)
Other versions
CA2979293A1 (en
Inventor
Timothy J. Kieffer
Jennifer E. BRUIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CCS Ventures Ltd
Original Assignee
CCS Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CCS Ventures Ltd filed Critical CCS Ventures Ltd
Publication of CA2979293A1 publication Critical patent/CA2979293A1/en
Application granted granted Critical
Publication of CA2979293C publication Critical patent/CA2979293C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2979293A 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d) Active CA2979293C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131540P 2015-03-11 2015-03-11
US62/131,540 2015-03-11
PCT/CA2016/000072 WO2016141460A1 (en) 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Publications (2)

Publication Number Publication Date
CA2979293A1 CA2979293A1 (en) 2016-09-15
CA2979293C true CA2979293C (en) 2022-01-04

Family

ID=56879832

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979293A Active CA2979293C (en) 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Country Status (7)

Country Link
US (2) US10772917B2 (enExample)
EP (1) EP3268016B1 (enExample)
JP (1) JP6847044B2 (enExample)
CN (1) CN107530379A (enExample)
AU (1) AU2016228894B2 (enExample)
CA (1) CA2979293C (enExample)
WO (1) WO2016141460A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951136B2 (en) 2017-12-12 2024-04-09 The Regents Of The University Of California Preservation of pancreatic islet grafts in the extrahepatic space
SG11202006837XA (en) 2018-01-18 2020-08-28 Daiichi Sankyo Co Ltd Dihydroindolizinone derivative
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
BR112021023389A2 (pt) 2019-05-22 2022-02-01 Cleveland Clinic Found Geração de células de endoderma de intestino anterior dorsal e domínio anterior
CN110585242A (zh) * 2019-10-15 2019-12-20 南通大学 多系分化持续应激细胞的应用、治疗糖尿病的药物及其制备方法
CN111411072B (zh) * 2020-03-09 2022-10-11 同济大学 SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN116018150A (zh) * 2020-08-28 2023-04-25 诺和诺德股份有限公司 用于筛选干细胞衍生的β样细胞的体外群体的方法及其新型标志物
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
EP1453954A4 (en) * 2001-11-09 2004-12-15 Artecel Sciences Inc Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof
IL165242A0 (en) * 2002-05-24 2005-12-18 Waratah Pharmaceuticals Inc Treatment for diabetes
AU2003268534A1 (en) * 2002-09-06 2004-03-29 Amcyte Inc. Cd56 positive human adult pancreatic endocrine progenitor cells
ES2564044T3 (es) 2003-06-27 2016-03-17 DePuy Synthes Products, Inc. Células posparto derivadas de tejido del cordón umbilical y métodos de preparación y uso de las mismas
CN1589904A (zh) * 2003-09-01 2005-03-09 北京大学 造血干细胞动员剂制备治疗糖尿病药物的用途
JP2006149380A (ja) * 2004-10-27 2006-06-15 Kobe Univ 遺伝子改変動物の新規用途
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
CN102016582A (zh) * 2006-10-31 2011-04-13 国家干细胞控股公司 鉴别、分离和利用来自成人胰腺的内分泌祖细胞的方法
DK2089005T3 (da) * 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
ATE523585T1 (de) 2007-11-27 2011-09-15 Lifescan Inc Differenzierung menschlicher embryonaler stammzellen
US20090280096A1 (en) * 2008-05-09 2009-11-12 Atsushi Kubo Pancreatic endocrine progenitor cells derived from pluripotent stem cells
NZ619520A (en) * 2009-02-13 2015-06-26 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
CN102695790A (zh) 2009-10-29 2012-09-26 詹森生物科技公司 多能干细胞
WO2011160066A1 (en) * 2010-06-17 2011-12-22 Regents Of The University Of Minnesota Production of insulin producing cells
DK2603226T3 (da) * 2010-08-12 2021-06-07 Janssen Biotech Inc Behandling af diabetes med endokrine pankreas-prækursorceller
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells

Also Published As

Publication number Publication date
WO2016141460A1 (en) 2016-09-15
EP3268016B1 (en) 2021-04-28
CN107530379A (zh) 2018-01-02
EP3268016A4 (en) 2018-12-12
JP6847044B2 (ja) 2021-03-24
JP2018507889A (ja) 2018-03-22
US10772917B2 (en) 2020-09-15
AU2016228894A1 (en) 2017-11-02
US20180055890A1 (en) 2018-03-01
CA2979293A1 (en) 2016-09-15
AU2016228894B2 (en) 2021-03-04
EP3268016A1 (en) 2018-01-17
US20210015872A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
Munk et al. Senescence-associated microRNAs
Corchero et al. Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics
Juvet et al. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning
EP4497472A3 (en) Production of fully functional mature beta cells from human pancreatic progenitors
TN2017000439A1 (en) Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites
WO2015048346A3 (en) Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control
PH12017501217A1 (en) Methods of treating retinal diseases
MX2021008464A (es) Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
SG10201804330YA (en) Engineered high-affinity human t cell receptors
WO2012071372A3 (en) Human antibodies to the glucagon receptor
WO2012021698A3 (en) Treatment of diabetes with pancreatic endocrine precursor cells
CY1120800T1 (el) Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων
WO2016144873A3 (en) Methods for cell labeling and medical imaging
WO2011017151A3 (en) Pairing processes for preparing alloreactive cytotoxic t cells
WO2015106295A3 (en) Enolase 1 (eno1) compositions and uses thereof
EP3268016A4 (en) Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)
WO2013056049A3 (en) Tubular prostheses
WO2017059177A3 (en) Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages
WO2019113375A3 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
HK1257882A1 (zh) 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法
ZA201907623B (en) T cells with reduced surface fucosylation and methods of making and using the same
WO2014014819A3 (en) Methods of treating glucose metabolism disorders
WO2014031745A3 (en) Materials and methods for modulating glucose uptake
Lin Iodine-125
WO2014132137A3 (en) Transgenic cell selection

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210211

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250107